Anti-NMDA receptor encephalitis medical therapy: Difference between revisions
(Created page with "__NOTOC__ {{Anti-NMDA receptor encephalitis}} {{CMG}} ==Overview== ==Medical Therapy== ==References== {{Reflist|2}} Category:Needs content Category:Rheumatology C...") |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Anti-NMDA receptor encephalitis}} | {{Anti-NMDA receptor encephalitis}} | ||
{{CMG}} | {{CMG}} AE {{DMakkar}} | ||
==Overview== | ==Overview== | ||
The treatment of anti-NMDAR encephalitis involves immunotherapy, tumor diagnosis, and excision. Early immunotherapy has shown to improve outcomes. Treatment options include corticosteroids, plasmapheresis, immunoglobulins, and rituximab. | |||
==Medical Therapy== | ==Medical Therapy== | ||
The treatment of anti-NMDAR encephalitis should include immunotherapy and the diagnosis and excision of the tumor. There is evidence that early immunotherapy may result in quicker recovery and decreased mortality. | |||
Current immunotherapy includes corticosteroids, immune plasmapheresis, intravenous immunoglobulins, and rituximab. | |||
==References== | ==References== | ||
| Line 12: | Line 16: | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
<ref name="pmid18851928">{{cite journal| author=Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M | display-authors=etal| title=Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. | journal=Lancet Neurol | year= 2008 | volume= 7 | issue= 12 | pages= 1091-8 | pmid=18851928 | doi=10.1016/S1474-4422(08)70224-2 | pmc=2607118 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18851928 }} </ref> | |||
<ref name="pmid23946310">{{cite journal| author=Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Bataller L | display-authors=etal| title=Late-onset anti-NMDA receptor encephalitis. | journal=Neurology | year= 2013 | volume= 81 | issue= 12 | pages= 1058-63 | pmid=23946310 | doi=10.1212/WNL.0b013e3182a4a49c | pmc=3795591 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23946310 }} </ref> | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 13:03, 13 May 2023
|
Anti-NMDA receptor encephalitis Microchapters |
|
Differentiating Anti-NMDA receptor encephalitis from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Anti-NMDA receptor encephalitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis medical therapy |
|
Directions to Hospitals Treating Anti-NMDA receptor encephalitis |
|
Risk calculators and risk factors for Anti-NMDA receptor encephalitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] AE Dheeraj Makkar, M.D.[2]
Overview
The treatment of anti-NMDAR encephalitis involves immunotherapy, tumor diagnosis, and excision. Early immunotherapy has shown to improve outcomes. Treatment options include corticosteroids, plasmapheresis, immunoglobulins, and rituximab.
Medical Therapy
The treatment of anti-NMDAR encephalitis should include immunotherapy and the diagnosis and excision of the tumor. There is evidence that early immunotherapy may result in quicker recovery and decreased mortality.
Current immunotherapy includes corticosteroids, immune plasmapheresis, intravenous immunoglobulins, and rituximab.
References
[1] [2] Template:WH Template:WS
- ↑ Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M; et al. (2008). "Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies". Lancet Neurol. 7 (12): 1091–8. doi:10.1016/S1474-4422(08)70224-2. PMC 2607118. PMID 18851928.
- ↑ Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Bataller L; et al. (2013). "Late-onset anti-NMDA receptor encephalitis". Neurology. 81 (12): 1058–63. doi:10.1212/WNL.0b013e3182a4a49c. PMC 3795591. PMID 23946310.